We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

05 Aug 2026 - 07 Aug 2026
18 Aug 2026 - 20 Aug 2026

Electrical Impedance Device Assists Colposcopy Screening

By HospiMedica International staff writers
Posted on 04 Feb 2013
An innovative device uses electrical impedance spectroscopy (EIS) to provide accurate and real-time results in the detection of neoplasias in cervical disease. More...


The ZedScan I device is designed to enable colposcopists to better target a biopsy site by providing a more accurate assessment of the cervix using EIS to measure the resistivity of cells, and so detect changes as cells progress from normal to precancerous and then to cancerous. Benefits of the device include better differentiation between high-grade and low-grade abnormalities, reduction in the number of biopsies required, better predictive values when compared to colposcopic impression, and the potential to move to a "See and Treat" model for cervical intraepithelial neoplasia (CIN) 2/3 diagnosis.

The ZedScan I will also enable colposcopists to better target a biopsy site by providing a more accurate assessment of the cervix, thereby reducing the number of unnecessary diagnostic biopsies. The device consists of a cordless handheld device and a base unit, together with a single-use disposable sleeve. Among the features of the device are wipe-clean surfaces, an on-board user interface, built-in quality control tests, and real time results that can be transferred to a personal computer (PC) for data storage and report generation. The ZedScan I device is a product of Zilico (Sheffield, United Kingdom).

“ZedScan I has the potential to make a significant impact on how women are managed within the cervical cancer pathway,” said Sameer Kothari, CEO of Zilico. “This potential has clearly been recognized as we've received significant from across the globe over the last few months.”

Currently, the cervical cancer diagnostic pathway requires that women have an initial screening test and, if any abnormality is identified, they are then referred for a more detailed examination carried out using colposcopy binocular microscopy, a relatively subjective procedure to distinguish those who need a biopsy confirm the presence of high grade pre-cancerous lesions; clinicians often take multiple biopsies to confirm disease due to the inherent subjectivity.

Related Links:
Zilico



Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Vessel Sealing Instrument
ERGOseal
Blood Gas Analyzer
i-Check200
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.